Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure

The envelope of Human Immunodeficiency Virus type 1 (HIV-1) consists of a liquid-ordered membrane enriched in raft lipids and containing the viral glycoproteins. Previous studies demonstrated that changes in viral membrane lipid composition affecting membrane structure or curvature can impair infect...

Full description

Bibliographic Details
Main Authors: Jon Ander Nieto-Garai, Bärbel Glass, Carmen Bunn, Matthias Giese, Gary Jennings, Beate Brankatschk, Sameer Agarwal, Kathleen Börner, F. Xabier Contreras, Hans-Joachim Knölker, Claudia Zankl, Kai Simons, Cornelia Schroeder, Maier Lorizate, Hans-Georg Kräusslich
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.01983/full
id doaj-fd4444ee06e94b2faeeb9a3b8b783731
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Jon Ander Nieto-Garai
Bärbel Glass
Carmen Bunn
Matthias Giese
Gary Jennings
Beate Brankatschk
Beate Brankatschk
Sameer Agarwal
Sameer Agarwal
Kathleen Börner
F. Xabier Contreras
F. Xabier Contreras
Hans-Joachim Knölker
Hans-Joachim Knölker
Claudia Zankl
Claudia Zankl
Kai Simons
Cornelia Schroeder
Cornelia Schroeder
Cornelia Schroeder
Maier Lorizate
Hans-Georg Kräusslich
spellingShingle Jon Ander Nieto-Garai
Bärbel Glass
Carmen Bunn
Matthias Giese
Gary Jennings
Beate Brankatschk
Beate Brankatschk
Sameer Agarwal
Sameer Agarwal
Kathleen Börner
F. Xabier Contreras
F. Xabier Contreras
Hans-Joachim Knölker
Hans-Joachim Knölker
Claudia Zankl
Claudia Zankl
Kai Simons
Cornelia Schroeder
Cornelia Schroeder
Cornelia Schroeder
Maier Lorizate
Hans-Georg Kräusslich
Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
Frontiers in Immunology
lipidomimetics
HIV-1 envelope
lipid raft modulation
laurdan
membrane order
HIV fusion inhibitors
author_facet Jon Ander Nieto-Garai
Bärbel Glass
Carmen Bunn
Matthias Giese
Gary Jennings
Beate Brankatschk
Beate Brankatschk
Sameer Agarwal
Sameer Agarwal
Kathleen Börner
F. Xabier Contreras
F. Xabier Contreras
Hans-Joachim Knölker
Hans-Joachim Knölker
Claudia Zankl
Claudia Zankl
Kai Simons
Cornelia Schroeder
Cornelia Schroeder
Cornelia Schroeder
Maier Lorizate
Hans-Georg Kräusslich
author_sort Jon Ander Nieto-Garai
title Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
title_short Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
title_full Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
title_fullStr Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
title_full_unstemmed Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
title_sort lipidomimetic compounds act as hiv-1 entry inhibitors by altering viral membrane structure
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2018-09-01
description The envelope of Human Immunodeficiency Virus type 1 (HIV-1) consists of a liquid-ordered membrane enriched in raft lipids and containing the viral glycoproteins. Previous studies demonstrated that changes in viral membrane lipid composition affecting membrane structure or curvature can impair infectivity. Here, we describe novel antiviral compounds that were identified by screening compound libraries based on raft lipid-like scaffolds. Three distinct molecular structures were chosen for mode-of-action studies, a sterol derivative (J391B), a sphingosine derivative (J582C) and a long aliphatic chain derivative (IBS70). All three target the viral membrane and inhibit virus infectivity at the stage of fusion without perturbing virus stability or affecting virion-associated envelope glycoproteins. Their effect did not depend on the expressed envelope glycoproteins or a specific entry route, being equally strong in HIV pseudotypes carrying VSV-G or MLV-Env glycoproteins. Labeling with laurdan, a reporter of membrane order, revealed different membrane structure alterations upon compound treatment of HIV-1, which correlated with loss of infectivity. J582C and IBS70 decreased membrane order in distinctive ways, whereas J391B increased membrane order. The compounds' effects on membrane order were reproduced in liposomes generated from extracted HIV lipids and thus independent both of virion proteins and of membrane leaflet asymmetry. Remarkably, increase of membrane order by J391B required phosphatidylserine, a lipid enriched in the HIV envelope. Counterintuitively, mixtures of two compounds with opposite effects on membrane order, J582C and J391B, did not neutralize each other but synergistically inhibited HIV infection. Thus, altering membrane order, which can occur by different mechanisms, constitutes a novel antiviral mode of action that may be of general relevance for enveloped viruses and difficult to overcome by resistance development.
topic lipidomimetics
HIV-1 envelope
lipid raft modulation
laurdan
membrane order
HIV fusion inhibitors
url https://www.frontiersin.org/article/10.3389/fimmu.2018.01983/full
work_keys_str_mv AT jonandernietogarai lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT barbelglass lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT carmenbunn lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT matthiasgiese lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT garyjennings lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT beatebrankatschk lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT beatebrankatschk lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT sameeragarwal lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT sameeragarwal lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT kathleenborner lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT fxabiercontreras lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT fxabiercontreras lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT hansjoachimknolker lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT hansjoachimknolker lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT claudiazankl lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT claudiazankl lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT kaisimons lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT corneliaschroeder lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT corneliaschroeder lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT corneliaschroeder lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT maierlorizate lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT hansgeorgkrausslich lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
_version_ 1725184210356928512
spelling doaj-fd4444ee06e94b2faeeb9a3b8b7837312020-11-25T01:08:07ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-09-01910.3389/fimmu.2018.01983402042Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane StructureJon Ander Nieto-Garai0Bärbel Glass1Carmen Bunn2Matthias Giese3Gary Jennings4Beate Brankatschk5Beate Brankatschk6Sameer Agarwal7Sameer Agarwal8Kathleen Börner9F. Xabier Contreras10F. Xabier Contreras11Hans-Joachim Knölker12Hans-Joachim Knölker13Claudia Zankl14Claudia Zankl15Kai Simons16Cornelia Schroeder17Cornelia Schroeder18Cornelia Schroeder19Maier Lorizate20Hans-Georg Kräusslich21Departamento de Bioquímica y Biología Molecular, Instituto Biofisika (CSIC, UPV/EHU), Universidad del País Vasco, Bilbao, SpainDepartment of Infectious Diseases, Virology, Universitätsklinikum Heidelberg, Heidelberg, GermanyJADO Technologies, Dresden, GermanyJADO Technologies, Dresden, GermanyJADO Technologies, Dresden, GermanyJADO Technologies, Dresden, GermanyMembrane Biochemistry Group, Paul-Langerhans-Institute Dresden, Helmholtz Zentrum München at the University Hospital and Faculty of Medicine Carl Gustav Carus, Dresden, GermanyJADO Technologies, Dresden, GermanyDepartment of Chemistry, Technische Universität Dresden, Dresden, GermanyDepartment of Infectious Diseases, Virology, Universitätsklinikum Heidelberg, Heidelberg, GermanyDepartamento de Bioquímica y Biología Molecular, Instituto Biofisika (CSIC, UPV/EHU), Universidad del País Vasco, Bilbao, SpainIkerbasque, Basque Foundation for Science, Bilbao, SpainJADO Technologies, Dresden, GermanyDepartment of Chemistry, Technische Universität Dresden, Dresden, GermanyJADO Technologies, Dresden, GermanyDepartment of Chemistry, Technische Universität Dresden, Dresden, GermanyMax Planck Institute of Molecular Cell Biology and Genetics, Dresden, GermanyJADO Technologies, Dresden, GermanyMax Planck Institute of Molecular Cell Biology and Genetics, Dresden, GermanyDepartment of Anatomy, Medical Faculty Carl-Gustav-Carus, Technische Universität Dresden, Dresden, GermanyDepartamento de Bioquímica y Biología Molecular, Instituto Biofisika (CSIC, UPV/EHU), Universidad del País Vasco, Bilbao, SpainDepartment of Infectious Diseases, Virology, Universitätsklinikum Heidelberg, Heidelberg, GermanyThe envelope of Human Immunodeficiency Virus type 1 (HIV-1) consists of a liquid-ordered membrane enriched in raft lipids and containing the viral glycoproteins. Previous studies demonstrated that changes in viral membrane lipid composition affecting membrane structure or curvature can impair infectivity. Here, we describe novel antiviral compounds that were identified by screening compound libraries based on raft lipid-like scaffolds. Three distinct molecular structures were chosen for mode-of-action studies, a sterol derivative (J391B), a sphingosine derivative (J582C) and a long aliphatic chain derivative (IBS70). All three target the viral membrane and inhibit virus infectivity at the stage of fusion without perturbing virus stability or affecting virion-associated envelope glycoproteins. Their effect did not depend on the expressed envelope glycoproteins or a specific entry route, being equally strong in HIV pseudotypes carrying VSV-G or MLV-Env glycoproteins. Labeling with laurdan, a reporter of membrane order, revealed different membrane structure alterations upon compound treatment of HIV-1, which correlated with loss of infectivity. J582C and IBS70 decreased membrane order in distinctive ways, whereas J391B increased membrane order. The compounds' effects on membrane order were reproduced in liposomes generated from extracted HIV lipids and thus independent both of virion proteins and of membrane leaflet asymmetry. Remarkably, increase of membrane order by J391B required phosphatidylserine, a lipid enriched in the HIV envelope. Counterintuitively, mixtures of two compounds with opposite effects on membrane order, J582C and J391B, did not neutralize each other but synergistically inhibited HIV infection. Thus, altering membrane order, which can occur by different mechanisms, constitutes a novel antiviral mode of action that may be of general relevance for enveloped viruses and difficult to overcome by resistance development.https://www.frontiersin.org/article/10.3389/fimmu.2018.01983/fulllipidomimeticsHIV-1 envelopelipid raft modulationlaurdanmembrane orderHIV fusion inhibitors